Kawasaki Kids on X: "Day 4 of Kawasaki Disease Awareness Month IVIG Treatment for Kawasaki Disease is the most widely used treatment to stop the fever and inflammation in the child's body.
Figure 1 | Archives of Disease in Childhood
Clinical characteristics in Kawasaki disease related to intravenous... | Download Table
Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study - The Lancet Child & Adolescent Health
IJMS | Free Full-Text | Anemia in Kawasaki Disease: Hepcidin as a Potential Biomarker
Understanding Kawasaki Disease
Various adjuncts to IVIg help treat coronary artery abnormalities in pediatric Kawasaki disease | MDedge Pediatrics
JCI - Immune response to intravenous immunoglobulin in patients with Kawasaki disease and MIS-C
Revised recommendations of the Italian Society of Pediatrics about the general management of Kawasaki disease | Italian Journal of Pediatrics | Full Text
RAISE Study: New evidence of Kawasaki disease's treatment
Current pharmacological intervention and development of targeting IVIG resistance in Kawasaki disease | Semantic Scholar
Diagnostics | Free Full-Text | Intravenous Immunoglobulin in Kawasaki Disease—Evolution and Pathogenic Mechanisms
Treatment of Kawasaki disease | Download Table
Pharmacologic interventions for Kawasaki disease in children: A network meta-analysis of 56 randomized controlled trials - eBioMedicine
Revised recommendations of the Italian Society of Pediatrics about the general management of Kawasaki disease | Italian Journal of Pediatrics | Full Text
Kawasaki Dis Canada on X: "Approximately 10% to 20% of patients with Kawasaki disease develop recrudescent or persistent fever at least 36 hours after the end of their IVIG infusion and are
Intravenous Immunoglobulin for the Treatment of Kawasaki Disease | Pediatric Annals
The Lancet - Kawasaki disease is a self-limited vasculitis that is the most common cause of acquired heart disease in children in developed countries. Although intravenous immunoglobulin (IVIG) is effective therapy, 10–20%
Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a
Intravenous Immunoglobulin for the Treatment of Kawasaki Disease | Pediatric Annals
Kawasaki disease: guidelines of Italian Society of Pediatrics, part II - treatment of resistant forms and cardiovascular complications, follow-up, lifestyle and prevention of cardiovascular risks | Italian Journal of Pediatrics | Full Text
2021 ACR/VF Kawasaki Guidelines - Vasculitis Foundation
Treat acute Kawasaki disease with aspirin plus intravenous immunoglobulin to improve coronary outcomes | SpringerLink
Flow chart reference for the management of refractory and incomplete... | Download Scientific Diagram
Management of Kawasaki disease | Archives of Disease in Childhood
Frontiers | Kawasaki Disease
